GlassScriptPhysician profile
Gregory L Derusso
NPI 1316959141
$2,811.28
in general payments reported to CMS, 2019-2025
35 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.73 · 2020: $152 · 2021: $525 · 2022: $658 · 2023: $810 · 2024: $224 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,422 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,422.27 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $766.56 | 2021-2025 | Vraylar, Qulipta, Ubrelvy |
| Glaxosmithkline, LLC. | $334.07 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $200.74 | 2021-2023 | Spiriva, Spiriva Respimat |
| Astellas Pharma US INC | $187.69 | 2022-2025 | Veozah |
| Lilly USA, LLC | $162.48 | 2022-2025 | Mounjaro, Trulicity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $136.22 | 2021-2024 | Trulance, Xifaxan, Cycloset |
| Bayer Healthcare Pharmaceuticals INC. | $131.73 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $113.26 | 2021-2022 | |
| Novo Nordisk INC | $96.51 | 2020-2024 | Ozempic, Rybelsus |
| Abbott Laboratories | $87.19 | 2021-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $53.73 | 2019 | |
| Allergan, INC. | $48.73 | 2020 | |
| Sanofi-Aventis U.S. LLC | $47.98 | 2021-2023 | |
| Pfizer INC. | $47.12 | 2021-2025 | |
| Lundbeck LLC | $31.01 | 2023-2025 | Rexulti |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $29.98 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $29.80 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $25.17 | 2020 | |
| Eisai INC. | $24.76 | 2020 | |
| Axsome Therapeutics, INC. | $22.35 | 2023 | Auvelity |
| Phathom Pharmaceuticals, INC. | $21.74 | 2024 | Voquezna |
| Bausch Health US, LLC | $21.20 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.19 | 2021 | |
| Dexcom, INC. | $18.21 | 2025 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $17.29 | 2025 | Cologuard Collection Kit |
| Currax Pharmaceuticals LLC | $16.36 | 2025 | Contrave |
| Sumitomo Pharma America, INC. | $16.20 | 2023-2024 | Gemtesa |
| Astrazeneca Pharmaceuticals LP | $15.75 | 2021 | |
| Amgen INC. | $15.00 | 2024 | Repatha, Otezla |
| E.R. Squibb & Sons, L.L.C. | $14.78 | 2021 | |
| Mylan Specialty L.P. | $13.98 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $13.83 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $11.13 | 2021 | |
| Corium, LLC | $10.61 | 2023 | Adlarity |
| Gilead Sciences, INC. | $7.93 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Derusso listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.